Promyelocytic crisis of chronic myelogenous leukaemia during imatinib mesylate treatment.
An untreated 66-year-old woman with chronic myelogenous leukaemia (CML) in the chronic phase was initially given imatinib mesylate, rapidly achieving a good cytogenetic response with treatment. However, acute promyelocytic leukaemia complicated by a disseminated intravascular coagulation occurred 9 months after beginning imatinib treatment. Promyelocytic crisis of CML was diagnosed by demonstration of both BCR/ABL and PML/RAR alpha chimeric genes in leukaemic cells by karyotypic and fluorescence in situ hybridization analysis. Clonal evolution with addition of the PML/RAR alpha translocation may have arisen in the early chronic phase of CML, with expansion of this clone during imatinib treatment. Promyelocytic crisis of CML is rare; furthermore, we know of no previous report of promyelocytic crisis occurring during treatment with imatinib.
Oku
Eijiro
E
Division of Haematology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.
Imamura
Rie
R
Nagata
Shuichiro
S
Takata
Yuka
Y
Seki
Ritsuko
R
Otsubo
Korenori
K
Hashiguchi
Michitoshi
M
Osaki
Koichi
K
Yakushiji
Kazuaki
K
Yoshimoto
Kohji
K
Ogata
Hideaki
H
Sata
Michio
M
Okamura
Takashi
T
D000368:Aged; D000970:Antineoplastic Agents; D001549:Benzamides; D005434:Flow Cytometry; D006801:Humans; D000068877:Imatinib Mesylate; D016130:Immunophenotyping; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D020133:Reverse Transcriptase Polymerase Chain Reaction
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate